[EN] IMIDAZOPYRROLOPYRIDINE AS INHIBITORS OF THE JAK FAMILY OF KINASES<br/>[FR] IMIDAZOPYRROLOPYRIDINE EN TANT QU'INHIBITEURS DE LA FAMILLE JAK DE KINASES
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2018112382A1
公开(公告)日:2018-06-21
2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.
The present invention provides a pyrazole compound represented by the formula (I):
wherein ring A
0
is a pyrazole ring optionally further having 1 or 2 substituents; R
a
is a substituted carbamoyl group; and R
b
is an optionally substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the prophylaxis or treatment of GSK-3β related pathology or disease, and a GSK-3β inhibitor including same.
COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
申请人:Plexxikon Inc.
公开号:US20170158690A1
公开(公告)日:2017-06-08
Disclosed are compounds of Formula I:
or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein Z
2
, Z
3
, and Z
5
are as described herein, compositions thereof, and uses thereof.
[EN] HETEROCYCLIC GLP-1 AGONISTS<br/>[FR] AGONISTES HÉTÉROCYCLIQUES DE GLP-1
申请人:GASHERBRUM BIO INC
公开号:WO2021160127A1
公开(公告)日:2021-08-19
Provided are GLP-1 agonists of Formula (I) or (II), including pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions, and methods of using the same.
提供了公式(I)或(II)的GLP-1激动剂,包括其药用盐和溶剂,药物组合物以及使用它们的方法。
Small Molecule Inhibitors of the JAK Family of Kinases
申请人:Janssen Pharmaceutica NV
公开号:US20180170931A1
公开(公告)日:2018-06-21
2-((1r,4r)-4-(imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(6H)-yl)cyclohexyl)acetonitrile compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions mediated by JAK, such as inflammatory bowel disease.